Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0471-0119 H in Type 1 Diabetes
NCT06809621Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0471-0119 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the basal-corrected glucose infusion rate-time curve from 0 to 1 hour. Started Jan 2025; status: completed.
02
Drugs
NNC0471-0119
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06809621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809621.